GO
Loading...

Enter multiple symbols separated by commas

Stocks Novartis AG

More

  • July 24- The U.S. Food and Drug Administration approved Novartis AG's oral pill to treat the most common form of advanced skin cancer. Roche Holding AG's Erivedge was the first pill to be approved in 2012 by the FDA for the condition. One in five Americans are likely to develop skin cancer in their lifetime, according to the American Academy of Dermatology.

  • FDA approves Novartis's advanced skin cancer drug Friday, 24 Jul 2015 | 12:19 PM ET

    July 24- The U.S. Food and Drug Administration approved Novartis AG's oral pill to treat the most common form of advanced skin cancer.

  • Do your investments operate in China? Read this Friday, 24 Jul 2015 | 12:09 PM ET
    A worker repairs steam locomotive parts in Fuxin coal mine locomotive repair plant in Fuxin, China.

    From software companies to drugmakers to fast food chains, economic weakness in China is denting multinationals' financials this earnings season.

  • Novartis earnings fall, CEO focuses on heart drug Thursday, 23 Jul 2015 | 6:58 PM ET
    Joe Jimenez, CEO of Novartis, at 2015 WEF in Davos, Switzerland.

    Novartis saw sales fall in Q2, but it's optimistic about its pipeline, particularly heart disease drug Entresto, CEO Joe Jimenez says.

  • July 23- Eli Lilly and Co's quarterly sales rose for the first time in seven quarters, helped by demand for its new diabetes and cancer drugs as well as the acquisition of Novartis AG's animal health business. Lilly's net profit fell to $600.8 million, or 56 cents per share, from $733.5 million, or 68 cents per share, a year earlier. It also bumped up the lower end of its...

  • July 23- Eli Lilly and Co said its quarterly revenue rose about 1 percent, helped by demand for its new cancer and diabetes treatments and the acquisition of Novartis AG's animal health business. The Indianapolis- based drugmaker's net profit fell to $600.8 million, or 56 cents per share, in the second quarter ended June 30, from $733.5 million, or 68 cents per share, a...

  • *Wall Street slides with earnings in focus. Stocks on Wall Street fell, with results from bellwethers IBM and United Technologies weighing the most on the S&P 500, while Apple slumped 7 percent late after posting earnings. "For the first time in a while fundamentals seem to be driving the action today in an otherwise very quiet macro backdrop and probably will...

  • NEW YORK, July 21- Novartis AG unit Sandoz must wait until Sept. 2 to sell Zarxio, the first biosimilar drug to be approved in the United States and a copycat version of Amgen Inc's $1.2 billion- a-year anti-infection drug Neupogen, a U.S. appeals court said on Tuesday. The ruling stemmed from a lawsuit that Amgen filed last October in federal court in San Francisco in...

  • Europe stocks lose steam; earnings in focus Tuesday, 21 Jul 2015 | 11:30 AM ET
    Gold bars in Vienna, Austria

    European stocks closed lower in choppy trade on Tuesday, with investors eyeing earnings and commodity prices.

  • Early movers: TRV, UTX, VZ, RF, DEPO, NKE & more Tuesday, 21 Jul 2015 | 8:04 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • European shares fall, pulled down by drugmakers Tuesday, 21 Jul 2015 | 7:51 AM ET

    *Pharmaceuticals drop after Novartis results. LONDON, July 21- European shares retreated on Tuesday from their six-week high in the previous session, with the healthcare leading the market lower after Novartis reported quarterly incomes below analysts' expectations. Novartis dropped 2.1 percent after the Swiss drugmaker reported a weak performance by its...

  • Novartis' now offers generic MS drug: CEO Tuesday, 21 Jul 2015 | 6:13 AM ET
    Novartis' now offers generic MS drug: CEO

    Joe Jimenez, Novartis CEO, discusses the generic availability of its multiple-sclerosis drug Copaxone.

  • Novartis' new heart drug potential game changer: CEO Tuesday, 21 Jul 2015 | 6:09 AM ET
    Novartis' new heart drug potential game changer: CEO

    Joe Jimenez, Novartis CEO, discusses the pharma company's quarterly results and its new heart failure drug, Entresto.

  • *Gold gains after plunging over 4 pct to 5- yr lows. LONDON, July 21- Gold prices steadied on Tuesday after plunging more than 4 percent in recent sessions, but remained under pressure as the dollar touched a three-month high on firming expectations of an interest rate hike. "Greece may be easing us into the quieter summer months, however there is still plenty to focus...

  • July 21- Novartis remains bullish about prospects for its blockbuster cancer drug Afinitor, which achieved sales of $1.58 billion last year, despite competitors lining up to challenge its market position. The success of Opdivo could, therefore, push back the use of Afinitor as doctors try the newer option, reducing sales of the Novartis product.

  • *Novartis leads market lower after results. LONDON, July 21- European shares edged lower on Tuesday after hitting a six-week high in the previous session, with the healthcare sector leading the market lower after Novartis reported quarterly incomes below analysts' expectations. The STOXX Europe 600 Healthcare Index fell 1.0 percent, the top sectoral decliner...

  • Strong dollar hits Novartis; reports profit miss Tuesday, 21 Jul 2015 | 3:06 AM ET

    Swiss drugmaker Novartis reported second-quarter core net income that fell short of expectations on Tuesday, on the back of a stronger dollar.

  • Looking at bolt-on acquisitions: Novartis CEO Tuesday, 21 Jul 2015 | 1:45 AM ET
    Looking at bolt-on acquisitions: Novartis CEO

    Joe Jimenez, CEO of Novartis, says the company is looking for bolt-on acquisitions worth between $1 bilion to $3 billion, rather than mega-mergers.

  • Tuesday focus: Commodities crush vs earnings Monday, 20 Jul 2015 | 6:28 PM ET
    A trader works on the floor of the New York Stock Exchange.

    A gusher of corporate earnings reports could set the tone for stocks Tuesday, as traders keep an eye on the increasingly sloppy commodities markets.

  • *Paulson expected to put pressure on Syngenta board. July 15- Hedge fund Paulson& Co has taken a stake in Syngenta AG and could push for the Swiss pesticide maker's board to accept a takeover offer from U.S. seed company Monsanto Co, people familiar with the matter said. Monsanto, the world's largest seed company, has made a $45 billion bid for Syngenta that the Swiss...